{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:37:44Z","timestamp":1781105864184,"version":"3.54.1"},"reference-count":45,"publisher":"Japanese Society for Pediatric Endocrinology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pediatr Endocrinol"],"published-print":{"date-parts":[[2006]]},"DOI":"10.1297\/cpe.15.129","type":"journal-article","created":{"date-parts":[[2006,11,3]],"date-time":"2006-11-03T00:46:17Z","timestamp":1162514777000},"page":"129-135","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Bases of Diseases Characterized by Hypophosphatemia and Phosphaturia: New Understanding"],"prefix":"10.1297","volume":"15","author":[{"given":"Keiichi","family":"Ozono","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Michigami","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine, Osaka Medical Center and Institute for Maternal and Child Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Namba","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine"},{"name":"First Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehisa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Minoh City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"125","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Prie D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 2005;14:318-24.","DOI":"10.1097\/01.mnh.0000172716.41853.1e"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Laroche M, Boyer JF. Phosphate diabetes, tubular phosphate reabsorption and phosphatonins. Joint Bone Spine 2005;72:376-81.","DOI":"10.1016\/j.jbspin.2004.07.013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Brame LA, White KE, Econs MJ. Renal phosphate wasting disorders: clinical features and pathogenesis. Semin Nephrol 2004;24:39-47.","DOI":"10.1053\/j.semnephrol.2003.08.016"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004;65:1-14.","DOI":"10.1111\/j.1523-1755.2004.00355.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004;20:563-9.","DOI":"10.1016\/j.tig.2004.08.007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yu X, White KE. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev 2005;16:221-32.","DOI":"10.1016\/j.cytogfr.2005.01.002"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.3696"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cormier S, Leroy C, Delezoide AL, Silve C. Expression of fibroblast growth factors 18 and 23 during human embryonic and fetal development. Gene Expr Patterns 2005;5:569-73.","DOI":"10.1016\/j.modgep.2004.10.008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005;146:4647-56.","DOI":"10.1210\/en.2005-0670"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2443.2005.00853.x"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.101545198"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561-8.","DOI":"10.1172\/JCI200419081"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408903200"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005;146:5358-64.","DOI":"10.1210\/en.2005-0777"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15.","DOI":"10.1681\/ASN.2005111185"},{"issue":"6,Pt.1","key":"16","first-page":"G1036","volume":"289","author":"KOLEK OLGA I.","year":"2005","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9513","issn-type":"print"},{"key":"17","unstructured":"17. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone 2004;35:1192-9."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005;90:1519-24.","DOI":"10.1210\/jc.2004-1039"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1038\/81664"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001;60:2079-86.","DOI":"10.1046\/j.1523-1755.2001.00064.x"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1006\/geno.2000.6235"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kumar R. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr Opin Nephrol Hypertens 2002;11:547-53.","DOI":"10.1097\/00041552-200209000-00011"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 2005;90:1012-20.","DOI":"10.1210\/jc.2004-0357"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.","DOI":"10.1056\/NEJMoa020881"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-60.","DOI":"10.1210\/jc.2002-021105"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.102"},{"issue":"2","key":"27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","year":"1995","ISSN":"https:\/\/id.crossref.org\/issn\/1061-4036","issn-type":"print"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5084"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004;35:455-62.","DOI":"10.1016\/j.bone.2004.04.002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Cho HY, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y. A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 2005;58:329-33.","DOI":"10.1203\/01.PDR.0000169983.40758.7B"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003;285:E1-9.","DOI":"10.1152\/ajpendo.00016.2003"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1086\/499410"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1086\/499409"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kronenberg HM. NPT2a-the key to phosphate homeostasis. N Engl J Med 2002;347:1022-4.","DOI":"10.1056\/NEJMe020098"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.25.050304.092642"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.5372"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Chau H, El-Maadawy S, McKee MD, Tenenhouse HS. Renal calcification in mice homozygous for the disrupted type IIa Na\/Pi cotransporter gene Npt2. J Bone Miner Res 2003;18:644-57.","DOI":"10.1359\/jbmr.2003.18.4.644"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 2002;347:983-91.","DOI":"10.1056\/NEJMoa020028"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Jones A, Tzenova J, Frappier D, Crumley M, Roslin N, Kos C, et al. Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na\/Pi cotransporter NPT2 gene. J Am Soc Nephrol 2001;12:507-14.","DOI":"10.1681\/ASN.V123507"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200943200"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-004-0589-9"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 2005;90:2424-7.","DOI":"10.1210\/jc.2004-2238"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005;14:385-90.","DOI":"10.1093\/hmg\/ddi034"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683-92.","DOI":"10.1172\/JCI18399"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Kagitani K, Yamamoto T, Miki K, Matsumoto S, Shima M, Tajiri H, et al. Hypophosphatemic rickets accompanying congenital microvillous atrophy. J Bone Miner Res 1998;13:1946-52.","DOI":"10.1359\/jbmr.1998.13.12.1946"}],"container-title":["Clinical Pediatric Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/cpe\/15\/4\/15_4_129\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T04:30:01Z","timestamp":1628051401000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/cpe\/15\/4\/15_4_129\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1297\/cpe.15.129","relation":{},"ISSN":["0918-5739","1347-7358"],"issn-type":[{"value":"0918-5739","type":"print"},{"value":"1347-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}